Genus/£GNS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Genus
Genus PLC, trading under the ticker GNS on the London Stock Exchange, specializes in animal genetics and biotechnology. The company, founded in 1994 and headquartered in Basingstoke, United Kingdom, operates across multiple countries offering genetically superior pig and cattle breeding stock along with state-of-the-art in vitro fertilization products. Genus PLC aims to empower customers in the livestock sector to enhance the efficiency and profitability of their operations by providing innovative genetic solutions and services.
- Ticker
- £GNS
- Sector
- Health
- Primary listing
- LSE
- Employees
- 2,921
- Headquarters
- Basingstoke, United Kingdom
- Website
- www.genusplc.com
Genus Metrics
BasicAdvanced
£1.5B
5.42
£4.25
0.91
£0.33
1.43%
Price and volume
Market cap
£1.5B
Beta
0.91
52-week high
£32.20
52-week low
£19.43
Average daily volume
198K
Dividend rate
£0.33
Financial strength
Current ratio
2.215
Quick ratio
1.419
Long term debt to equity
0.122
Total debt to equity
0.14
Dividend payout ratio (TTM)
7.61%
Interest coverage (TTM)
3.80%
Profitability
EBITDA (TTM)
103.5
Gross margin (TTM)
43.17%
Net profit margin (TTM)
43.35%
Operating margin (TTM)
12.00%
Effective tax rate (TTM)
8.06%
Revenue per employee (TTM)
£230,000
Management effectiveness
Return on assets (TTM)
5.21%
Return on equity (TTM)
45.95%
Valuation
Price to earnings (TTM)
5.415
Price to revenue (TTM)
2.312
Price to book
1.98
Price to tangible book (TTM)
2.47
Price to free cash flow (TTM)
27.029
Free cash flow yield (TTM)
3.70%
Free cash flow per share (TTM)
0.852
Dividend yield (TTM)
1.43%
Growth
Revenue change (TTM)
-2.18%
Earnings per share change (TTM)
1,370.93%
3-year revenue growth (CAGR)
-1.55%
10-year revenue growth (CAGR)
5.42%
3-year earnings per share growth (CAGR)
103.42%
10-year earnings per share growth (CAGR)
18.13%
3-year dividend per share growth (CAGR)
3.23%
10-year dividend per share growth (CAGR)
5.10%
What the Analysts think about Genus
Analyst ratings (Buy, Hold, Sell) for Genus stock.
Analyst projections of the future price of Genus stock.
Bulls say / Bears say
FY26 adjusted profit before tax and adjusted earnings per share both rose 35%, while free cash flow climbed 52% and leverage fell to 0.4 times. The £60 million buyback and higher dividend show the stronger balance sheet is supporting shareholder returns. (London Stock Exchange)
PIC China royalty revenue grew 52%, and Genus estimates its market share rose from 3.4% to 5.4%. Its partnership with BCA gives it a route to build on that position in the world’s largest pig market. (Stock Analysis, London Stock Exchange)
Genus secured further approvals or favourable determinations for its PRRS-resistant pig in Argentina, Canada, Uruguay and Peru, and has started commercialisation in selected Latin American markets. If adoption broadens, the technology could add a new source of growth beyond its established genetics business. (London Stock Exchange)
FY27 profit is expected to be weighted towards the second half, as disease challenges affect North American pork production and weak Brazilian pork and global dairy prices weigh on markets. That makes near-term growth more exposed to a recovery in conditions later in the year. (London Stock Exchange, Investing.com)
PRP commercialisation still depends on regulatory progress in major markets including Mexico, Japan and China, and Genus has not given a timetable. Delays could push back the broader commercial opportunity even as launches begin in parts of Latin America. (London Stock Exchange, Stock Analysis)
At about 22 times earnings, the shares offer limited room for execution to disappoint if growth stays modest. Stifel described the stock as broadly up with events and maintained a Hold rating after the results. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2026.
Genus Financial Performance
Revenues and expenses
Genus Earnings Performance
Company profitability
Upcoming events
Funds containing Genus
AllGBPUSDEUR
Fund name | Fund size | £GNS weighting |
|---|---|---|
iShares FTSE 250£MIDD | £652M | 0.50% |
iShares Agribusiness$ISAG | $582M | 0.49% |
iShares Agribusiness€ISAE | $582M | 0.49% |
iShares Agribusiness£SPAG | $582M | 0.49% |
Vanguard FTSE 250£VMID | £1.5B | 0.46% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.